Introduction The promotion of medicinal cannabis products presents some specific challenges given that very few such...
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Pearce IP BioBlast® w/e 13 May 2022
04 May 22 | Amneal published its Q1 2022 financial results, reporting a 1% increase YoY in net revenue. Amneal...
Too late to challenge amendments once infringement proceedings commenced
Illinois Tool Works Inc v Airco Fasteners Pty Ltd [2022] FCA 495 Date:Court:Judge:5 May 2022Federal Court of...
When supply of a staple commercial product is not infringement
Hood v Down Under Enterprises International Pty Ltd [2022] FCAFC 69Date:Court:Judges:4 May 2022Full Federal Court of...
Medicinal Cannabis in Australia | Part 2: Patient access via the Special Access Scheme (SAS) and Authorised Prescriber (AP) pathways
Introduction As noted in part 1 of our blog series, the vast majority of medicinal cannabis products are not...
Pearce IP BioBlast® w/e 06 May 2022
29 Apr 22 | Merck announced that the EC has approved Keytruda® (pembrolizumab) in combination with chemotherapy (with...
Prototype demonstrations invalidate competitor’s patent
Rakman International Pty Ltd v Boss Fire & Safety Pty Ltd [2022] FCA 464Date:Court:Judge:29 April 2022Federal...
Psychedelic Medicines Part 1
Depression, anxiety and related disorders are serious conditions whose treatment is - in many cases - not adequately...
Medicinal Cannabis in Australia | Part 1: Available Products
Introduction Medicinal cannabis is now widely available in Australia. However, the vast majority of medicinal...
Pearce IP BioBlast® w/e 29 April 2022
21 Apr 22 | AU | Australia’s TGA granted orphan drug designation to Roche’s glofitamab. The TGA also provided...
Pearce IP BioBlast® w/e 22 April 2022
14 Apr 22 | CA | BIOJAMP announced the launch of SIMLANDI™/AVT02 (high-concentration, low volume, citrate-free...
Pharmacia’s Dynastat patent expires before injunction ordered; but validity challenge means section 19 certification is still issued
We recently reported on the decision in Pharmacia LLC v Juno Pharmaceuticals Pty Ltd [2022] FCA 92 in which the...
Artificial intelligence cannot be a patent inventor
Commissioner of Patents v Thaler [2022] FCAFC 62Date:Court:Judges:13 April 2022Full Court of the Federal Court of...
Pearce IP BioBlast w/e 15 April 2022
11 Apr 22 | CA | Celltrion announced the launch of Yuflyma® (high-concentration, low-volume, citrate-free and...
Interlocutory Injunction To Restrain Further Threats Of Patent Infringement Proceedings Granted In Car Park Scrap
In the first such judgment since the 1980s, Justice Moshinsky has granted an interlocutory injunction to prevent TMA...
Our 2022 Client Survey Results are in!
Thank you to all our clients who participated in the inaugural 2022 Pearce IP “We Hear You” survey. The responses we...